… third of all deaths from cancer worldwide. Like most cancers, lung cancer is a conglomeration
of … into small-cell lung cancer (SCLC, comprising 20% of lung cancers), and non-small-cell …

… We prospectively screened 2105 patients with non–small-cell lung cancer for EGFR mutations.
Patients with mutations were then considered for erlotinib treatment at a dose of 150 mg …

… As the advent of lung cancer screening in selected populations is a fairly recent
occurrence, a significant proportion of patients will be diagnosed with late-stage lung cancer. …

… stage lung cancer who undergo surgical resection of their NSCLC with somatic mutations of
… growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. …

… carcinoma showed the highest frequency among lung cancers, followed by squamous cell
… EGFR-mutated lung cancers following a comprehensive examination of 1,380 lung tumors, …

… To examine the role of EGFR TK domain mutations in lung cancer pathogenesis, we searched
for EGFR TK domain mutations in genomic DNA isolated from primary lung tumors from …

… We found that 40% of 277 unselected patients with lung cancer carried mutations in the
TK domain of the EGFR gene. More than 90% of the mutations were either deletions around …

… (in East Asians) of adenocarcinomas of the lung. Targeted therapy for these lung cancers
has been established based on evidence regarding mainly common mutations; that is, exon 19 …

… Lung cancer is one of the major causes of cancer deaths in the world with … lung cancers are
classified into two major types, small cell lung cancer (SCLC) and non–small cell lung cancer …

… lung cells. The high susceptibility to gefitinib treatment among EGFR-mutated lung cancers
indicates that such mutations … the mutations; it has been likened to ‘addiction to the mutated …